At a glance
ClinicalIndex Comparison RecordN/ACompleted· 66 enrolled
Drug / intervention
Innovative Supportedother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Medico-economic Evaluation of a "IsereADOM" Package of Services Versus Conventional Health and Social Monitoring, in the Care of a Population of People With Heart Failure in Isère.
In Brief
A clinical study evaluating Innovative Supported for Heart Failure. Completed, enrolled 66 participants across 2 sites.
Detailed Summary
The goal of this study is to evaluate the health and social benefit of innovative management - IsereADOM - versus conventional follow-up in patients with heart failure. There is a medico-economic goal too, is to perform a cost-utility analysis of the service bundle (IsereADOM) versus conventional 6-month community-based follow-up in a population with heart failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedMar 2018
Primary CompletionNov 2019
TodayJul 2026
First PostedMar 7, 2018
Enrollment StartNov 20, 2017
Primary CompletionNov 15, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.3 years ago
Interventions
Innovative Supportedother
addition of connected tools and stronger accompaniment to improve quality of life